http://pharmexec.findpharma.com/pharmexec/R%26D/Article/list/39724 Corporate strategies and tactics for more effective drug development. 2009-11-21T09:56:56Z http://pharmexec.findpharma.com/pharmexec/News+Analysis/Clinical-Trials-Find-Drug-Effective-In-Increasing-/ArticleStandard/Article/detail/642664?contextCategoryId=39724&ref=25 Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction. 2009-11-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472009/642664null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Rising-to-the-Challenge-in-RampD/ArticleStandard/Article/detail/642667?contextCategoryId=39724&ref=25 Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs. 2009-11-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472009/642667null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Innovation-Over-Imitation/ArticleStandard/Article/detail/631735?contextCategoryId=39724&ref=25 As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631735/Picture-9_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631735null XML http://pharmexec.findpharma.com/pharmexec/R%26D/Biomarkers-Promises-and-Challenges/ArticleStandard/Article/detail/634081?contextCategoryId=39724&ref=25 Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development. 2009-10-14T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422009/634081null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Finding-the-Sweet-Spot/ArticleStandard/Article/detail/631734?contextCategoryId=39724&ref=25 How proper site activation and site enrollment can help you get the most from clinical trials. 2009-10-02T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631734/Picture-10_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/631734null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/NHLBI-Cans-Sildenafil-Study-After-Reports-of-Sever/ArticleStandard/Article/detail/615239?contextCategoryId=39724&ref=25 Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra. 2009-07-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312009/615239null REMOTE http://pharmexec.findpharma.com/pharmexec/R%26D/The-Rx-for-RampD/ArticleStandard/Article/detail/613032?contextCategoryId=39724&ref=25 The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies? 2009-07-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/302009/613032null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Statins-Get-Boost-from-New-Study/ArticleStandard/Article/detail/613031?contextCategoryId=39724&ref=25 Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal. 2009-07-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/302009/613031null REMOTE http://pharmexec.findpharma.com/pharmexec/R%26D/Swallowing-the-Innovators-Rx/ArticleStandard/Article/detail/608965?contextCategoryId=39724&ref=25 Capitalize on the new age in healthcare with "disruptive innovation." 2009-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608965/PE0709_innovators_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/608965null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/ASCO-Roundup-Winners-Losers-and-Also-Rans/ArticleStandard/Article/detail/601559?contextCategoryId=39724&ref=25 Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. 2009-06-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601559null REMOTE http://pharmexec.findpharma.com/pharmexec/R%26D/How-Evidence-Based-Medicine-is-Impacting-Global-Cl/ArticleStandard/Article/detail/589174?contextCategoryId=39724&ref=25 Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world 2009-03-24T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/132009/589174null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Pulls-Two-Late-stage-Drugs-from-Development/ArticleStandard/Article/detail/583389?contextCategoryId=39724&ref=25 A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them. 2009-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092009/583389null HTML http://pharmexec.findpharma.com/pharmexec/Web+Exclusives/Transforming-Clinicians-into-Industry-Leaders/ArticleStandard/Article/detail/581513?contextCategoryId=39724&ref=25 Could physician behavior have a positive impact on Drug Development? 2009-02-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072009/581513null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/Vaccines-for-All/ArticleStandard/Article/detail/580042?contextCategoryId=39724&ref=25 The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. 2009-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/580042/PE0209_vaccine_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Sheds-More-Staff/ArticleStandard/Article/detail/575379?contextCategoryId=39724&ref=25 Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good? 2009-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032009/575379null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Latest-Flu-Season-Sets-Tamiflu-Back-but-Doesnt-Kno/ArticleStandard/Article/detail/575384?contextCategoryId=39724&ref=25 The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral. 2009-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032009/575384null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Insuring-Global-Clinical-Trials/ArticleStandard/Article/detail/574732?contextCategoryId=39724&ref=25 As global regulators set up rules for liability insurance for clinical trials, the playing field has grown complex for sponsors. This article reviews the key issues and offers a look at how European, Asian, and Latin American countries handle clinical trial insurance. 2009-01-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022009/574732null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Merck-Submits-Request-to-Market-Gardasil-to-Men/ArticleStandard/Article/detail/574235?contextCategoryId=39724&ref=25 Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck. 2009-01-07T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022009/574235null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Site-Activation-The-Key-to-More-Efficient-Clinical/ArticleStandard/Article/detail/571374?contextCategoryId=39724&ref=25 A new study of hundreds of thousands of clinical trial records reveals that the overall length of a trial is directly related to how long it takes to activate the study sites - and that most companies are wasting precious weeks and even months in activation. Here's how to improve your performance. 2008-12-12T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502008/571374null HTML http://pharmexec.findpharma.com/pharmexec/Special+Reports/The-2008-Pipeline-Report/ArticleStandard/Article/detail/570131?contextCategoryId=39724&ref=25 We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond 2008-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492008/570131/PE1208_pipeline_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/R%26D/Gilding-Lilly/ArticleStandard/Article/detail/566074?contextCategoryId=39724&ref=25 Some say it's just another pharma facing its patent cliff. But others say this company's got it worse. With new CEO John Lechleiter in charge, can Lilly find its way back from the edge? 2008-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462008/566074/PE1108_lilly_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/R%26D/Evolving-Clinical-Trials/ArticleStandard/Article/detail/557676?contextCategoryId=39724&ref=25 Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency. 2008-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412008/557676null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Restructures-Oncology-Division/ArticleStandard/Article/detail/550565?contextCategoryId=39724&ref=25 Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit. 2008-09-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382008/550565null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Unleash-the-Dragon-2/ArticleStandard/Article/detail/548224?contextCategoryId=39724&ref=25 Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. 2008-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372008/548224/PE0908_china_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Article/Publish-or-Perish/ArticleStandard/Article/detail/548226?contextCategoryId=39724&ref=25 FDAAA means that you need to register clinical trials—and not only for publication planning 2008-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372008/548226null XML http://pharmexec.findpharma.com/pharmexec/R%26D/Roche-Touts-Positive-Data-for-Investigational-Diab/ArticleStandard/Article/detail/522918?contextCategoryId=39724&ref=25 Swiss pharma giant Roche was abuzz at ADA, announcing that its new diabetes treatment is set for Phase III trials and commenting on future plans for failed CETP inhibitor dalcetrapib. 2008-06-11T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242008/522918null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Risky-Cholesterol-Drug-Proves-Positive-for-Roche/ArticleStandard/Article/detail/507004?contextCategoryId=39724&ref=25 While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse? 2008-04-02T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142008/507004null HTML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/In-Praise-of-Independence-QampA-with-Roches-Dan-Za/ArticleStandard/Article/detail/501204?contextCategoryId=39724&ref=25 Roche has always gone its own way with biologics, deals, and new medicines. Now that the rest of industry has caught on, how can Roche stay ahead of its time? 2008-03-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102008/501204/pe0308_roche_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Rotating+Feature+Article/Fight-Resistance/ArticleStandard/Article/detail/490703?contextCategoryId=39724&ref=25 US officials think they can control MRSA and other "superbugs," but dangerous bacteria know no boundaries. What does the world do when its drugs stop working? 2008-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072008/490703/RESISTANCE_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/R%26D/BioMS-Medical-Signs-500-Million-Agreement-with-Lil/ArticleStandard/Article/detail/482390?contextCategoryId=39724&ref=25 Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. 2008-01-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022008/482390null HTML http://pharmexec.findpharma.com/pharmexec/Articles/Pharma-Forecast-Into-the-Woods/ArticleStandard/Article/detail/483070?contextCategoryId=39724&ref=25 Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts. 2008-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022008/483070/salesforce_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022008/483070/main_main.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022008/483070/forecast_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Articles/RampD-Learning-to-Share/ArticleStandard/Article/detail/483069?contextCategoryId=39724&ref=25 Novartis' Paul Herrling talks about how Big Pharma can learn from nonprofit R&D and collaborate to get an edge on the drug safety problem. 2008-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022008/483069/PE0108r+d_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Articles/The-Pharm-Exec-Pipeline-Report-2007/ArticleStandard/Article/detail/476125?contextCategoryId=39724&ref=25 You couldn't call it a gusher, but the pipeline has still has some life in it, and important new therapies are working their way toward approval. Have we turned the corner? Judge for yourself, with the help of this guide to 61 of the best new products in development. 2007-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482007/476125/pipeline_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/R%26D/Special-Delivery/ArticleStandard/Article/detail/476132?contextCategoryId=39724&ref=25 Getting innovative drugs into bodies just got a whole lot more interesting. Here's how the delivery biz is keeping up with pharma's R&D. 2007-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482007/476132/specialdelivery_flash_flash.jpg XML http://pharmexec.findpharma.com/pharmexec/Articles/Rethinking-Vaccines-QampA-with-Jane-Quinn-GlaxoSmi/ArticleStandard/Article/detail/476128?contextCategoryId=39724&ref=25 There are plenty of new vaccines on the market, but for patients to get maximum benefit from them, payers and even physicians need to rethink their roles in prevention. 2007-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482007/476128null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Duke-Partners-with-FDA-to-Modernize-Clinical-Trial/ArticleStandard/Article/detail/475929?contextCategoryId=39724&ref=25 In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient. 2007-11-29T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482007/475929null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lillys-New-Blood-Thinner-No-Blockbuster/ArticleStandard/Article/detail/470634?contextCategoryId=39724&ref=25 Safety Risks, Generic Threat Scale Down Big Hopes 2007-11-06T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/452007/470634null HTML http://pharmexec.findpharma.com/pharmexec/Current+Issue/India-vs-China/ArticleStandard/Article/detail/469185?contextCategoryId=39724&ref=25 Will CROs continue to operate in India, or will Novartis' pullout send them farther East? 2007-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442007/469185null XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/More-Confidencemdashor-Slower-Development/ArticleStandard/Article/detail/469184?contextCategoryId=39724&ref=25 FDAAA aims to restore public trust in drug safety regulation but may curb investment in R&D 2007-11-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442007/469184null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Eli-Lilly-Quietly-Suspends-Two-Trials/ArticleStandard/Article/detail/469014?contextCategoryId=39724&ref=25 The company halts two small pharmacodynamic trials of a key candidate just days before a major presentation of data. Is something wrong with prasugrel? And why is Lilly playing the news so close to the chest? 2007-10-31T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442007/469014null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Genzyme-Forms-Partnership-with-Overseas-Gene-Thera/ArticleStandard/Article/detail/469010?contextCategoryId=39724&ref=25 Genzyme will collaborate with Chinese biotech manufacturer Sunway to perform clinical trials and potentially produce the experimental gene therapy HIF-1a in China. 2007-10-31T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442007/469010null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Medtronic-Wins-Recommendation-for-Safer-Drug-Eluti/ArticleStandard/Article/detail/465613?contextCategoryId=39724&ref=25 FDA advisory panel notes high efficacy—and no thrombosis after six months—in clinical trials. Nonetheless, Medtronic's stents will be under close postapproval watch. 2007-10-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422007/465613null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/BMS-Snags-Biotech-Firm-Adnexus/ArticleStandard/Article/detail/461948?contextCategoryId=39724&ref=25 Adnexus' protein-building technology could spell new drugs and big profits for BMS--if the drug development engine works. 2007-10-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402007/461948null HTML http://pharmexec.findpharma.com/pharmexec/Articles/Its-Standards-Time/ArticleStandard/Article/detail/463120?contextCategoryId=39724&ref=25 The clinical trials space these days is an alphabet soup of technologies: CTMS (clinical trial management systems); CDM (clinical data management); CDR (clinical data repositories); eCTD (electronic common technical document); and many more. But the technology with the most promise for transforming the way clinical trials are performed (and for driving everyone mad throughout implementation) is EDC—electronic data capture. It's taken more than a decade, but today most big pharma companies—and a fair number of smaller ones—are using some form of EDC in clinical trials. The early adopters might have experienced some growing pains, but the benefits seem to be outweighing the high cost of implementation. Few companies would consider going back to paper-based trials. 2007-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402007/463120null XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Radio-Active/ArticleStandard/Article/detail/463112?contextCategoryId=39724&ref=25 David Barlow is the closest thing you can find to a pharma-industry ecologist. He takes companies that deal with technology that Big Pharma won't touch and turns them into drug powerhouses. 2007-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402007/463112null XML http://pharmexec.findpharma.com/pharmexec/Articles/RampD-Innovation-An-Answer-to-Cancer/ArticleStandard/Article/detail/463103?contextCategoryId=39724&ref=25 Cancer R&D IS booming right now. At a time of poor ratings on both Wall Street and Main Street, pharma can at least point proudly to its oncology pipeline as proof that it still takes big risks to make big advances against big killers—and win. According to a recent IMS report, the cancer pipeline contains 380 compounds, with nearly 100 in Phase III. The long-established standard of care—surgery, radiotherapy, and chemo—is fast giving way to a high-tech array of targeted therapies. These molecules and antibodies are designed to block specific disease pathways, and they are proving both far more effective and far more tolerable than the sledgehammer status quo. Since 1996, the overall survival rate for patients has jumped by 30 percent, from one-half to two-thirds. 2007-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402007/463103null XML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Boosts-Flu-Doses/ArticleStandard/Article/detail/458135?contextCategoryId=39724&ref=25 Drug company increases vaccine supply by 10 million in advance of influenza season 2007-09-19T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382007/458135null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/New-Rules-for-Asthma-Med-Makers/ArticleStandard/Article/detail/454640?contextCategoryId=39724&ref=25 NHLBI releases updated regulations for asthma treatment 2007-09-06T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362007/454640null HTML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Incentives-Incense-Industry-in-UK/ArticleStandard/Article/detail/455798?contextCategoryId=39724&ref=25 The Association of the British Pharmaceutical Industry is challenging the UK government over the financial incentives being offered by the Department of Health (DH) to encourage doctors to switch patients from on-patent medicines to specific generic alternatives. ABPI believes the way the incentives are structured contravenes EU law—if pharma companies were to offer similar payments, they would be in serious trouble. 2007-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372007/455798null XML http://pharmexec.findpharma.com/pharmexec/Articles/RampD-A-Merck-in-Progress/ArticleStandard/Article/detail/455801?contextCategoryId=39724&ref=25 That was the collective vow sworn by Big Pharma last December following Pfizer's $1 billion–down–the–tubes withdrawal of the cholesterol compound they had touted as the most important drug of the decade. The question is, What's the right organizational construct to support innovation—or at least to stop Phase III failures? 2007-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372007/455801null XML http://pharmexec.findpharma.com/pharmexec/Global+Report/Make-Resistance-Futile/ArticleStandard/Article/detail/446935?contextCategoryId=39724&ref=25 Scare stories about antibiotic-resistant bacteria are all too common in the mass media these days. In the United Kingdom alone, the number of deaths from methicillin-resistant Staphylococcus aureus almost doubled between 2001 and 2005 to more than 2,000. The situation with Clostridium difficile is even worse, with UK deaths tripling to almost 4,000 over the same period. The big problem is that the incidence is growing, yet few antibiotics are being developed that will be able to kill the resistant bacteria. 2007-07-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312007/446935null XML http://pharmexec.findpharma.com/pharmexec/R%26D/Tomorrows-Drugs/ArticleStandard/Article/detail/446938?contextCategoryId=39724&ref=25 Have you heard the rumors that all the drugs have already been discovered? Well, forget it. Maybe some of the low-hanging fruit is gone—but in the last few years, science has opened up thousands of new targets, while new technologies have made it possible to treat disease in unprecedented ways. 2007-07-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312007/446938null XML http://pharmexec.findpharma.com/pharmexec/Thought+Leader/Connected-Markets-Rob-Dhoble/ArticleStandard/Article/detail/442274?contextCategoryId=39724&ref=25 We'll see a more coordinated, worldwide platform not just for marketing, but for R&D and regulatory because of the harmonization that is slowly coming, primarily between Japan, Europe, and the United States 2007-07-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/292007/442274null XML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Glaxo-Gives-High-Five-to-Cancer-Market/ArticleStandard/Article/detail/437611?contextCategoryId=39724&ref=25 Big crop of oncology drugs is the fruit of Garnier's excellent restructuring 2007-06-27T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/262007/437611null HTML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Global-Access-for-Pfizers-New-HIV-Drug/ArticleStandard/Article/detail/435689?contextCategoryId=39724&ref=25 Maraviroc's promise shows the value of expanded-access programs 2007-06-20T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252007/435689null HTML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Whats-Hot-and-Whats-Not-in-Oncology/ArticleStandard/Article/detail/432937?contextCategoryId=39724&ref=25 The take-home from the American Society of Clinical Oncology. 2007-06-13T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232007/432937null HTML http://pharmexec.findpharma.com/pharmexec/R%26D+Articles/Clinical-Trials-Under-Scrutiny/ArticleStandard/Article/detail/429165?contextCategoryId=39724&ref=25 Payment to physicians and other conflicts of interest Are ripe areas of concern, particularly when they raise doubt over the integrity of research findings 2007-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/212007/429165null XML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Companies-Forge-Ahead-with-Cancer-Vaccine-RampD/ArticleStandard/Article/detail/428442?contextCategoryId=39724&ref=25 Provenge setback not deterring others in the field. 2007-05-23T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/212007/428442null HTML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Pharma-Gets-Wired-for-Clinical-Trials/ArticleStandard/Article/detail/426643?contextCategoryId=39724&ref=25 Companies are poised to speed up investments in electronic data capture. 2007-05-16T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/202007/426643null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/Kid-Tested-Government-Approved/ArticleStandard/Article/detail/423216?contextCategoryId=39724&ref=25 As the industry focuses its attention on the upcoming renewal of the Prescription Drug User Fee Act (PDUFA), there is a tendency to overlook two other significant pharmaceutical programs coming up for renewal and a related piece of legislation that has been introduced: 2007-05-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182007/423216/kid_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182007/423216null XML http://pharmexec.findpharma.com/pharmexec/R%26D+News/Generic-Biologics-Booked-for-Arrival/ArticleStandard/Article/detail/419953?contextCategoryId=39724&ref=25 With legislation pending in Congress, generics makers begin investments in follow-on protein drugs. 2007-04-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/162007/419953null HTML http://pharmexec.findpharma.com/pharmexec/Articles/Virus-as-Viable-Drug/ArticleStandard/Article/detail/401668?contextCategoryId=39724&ref=25 A lot of the viruses that are being worked on today are genetically engineered to target the cell and crank out a drug that will kill it. But in our case, we don’t need a drug—the reovirus does it all by itself. 2007-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052007/401668/TN_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052007/401668null XML http://pharmexec.findpharma.com/pharmexec/Toolkit/Toolkit-Going-Head-to-Head/ArticleStandard/Article/detail/401660?contextCategoryId=39724&ref=25 Comparative drug tests make pharma see red. But market pressure to prove a drug's real-world value is likely to force even the most stubborn firm into the ring. Why be bull-headed? Adaptive trials can cut cost, time, and risk in half. 2007-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052007/401660null XML http://pharmexec.findpharma.com/pharmexec/Thought+Leader/Thoughtleader-John-Bailye-Dendrite/ArticleStandard/Article/detail/401658?contextCategoryId=39724&ref=25 Doctors want to know what's hot in the market, not read a new brochure on a nine-year product that doctors have already been using. 2007-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052007/401658null XML http://pharmexec.findpharma.com/pharmexec/Articles/Pipeline/ArticleStandard/Article/detail/389274?contextCategoryId=39724&ref=25 This year's Pipeline Report profiles 32 compounds that are the early fruit of pharma's investment in targeted drug design. In diabetes, HIV, hepatitis C—and especially oncology—vibrant R&D is set to revolutionize treatment with new classes of drugs over the coming decade. We spotlight today's geeky names—the DPP-IVs and MK-0518s, the Tykerbs and Telaprevirs—that are most likely to be tomorrow's glam blockbusters. Even the year's downers—we're still waiting on Acomplia, Exubera is failing to live up to the hype—are reminders of how improvements in drug development, such as Phase 0, are helping industry in its drive to become more effective. Although riskier than squeezing me-too drugs out of proven products, targeted R&D is lighting pathways not only to cures of killer diseases but to a fresh paradigm of progress and profits, and to renewed confidence in the pharmaceutical industry. From where we stand, the future looks bright. 2006-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482006/389274/TN_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/482006/389274null XML http://pharmexec.findpharma.com/pharmexec/R%26D/PHARM-EXEC-PODCAST-Drug-Repositioning-at-Roche-A-N/ArticleStandard/Article/detail/380375?contextCategoryId=39724&ref=25 An executive interview with Lee Babiss PhD, VP, Preclinical R & D of Hoffmann-La Roche, Inc, conducted by Patrick Clinton, Editor in Chief of Pharmaceutical Executive. Tune in and hear a real-world perspective on drug repositioning as a new way of filling late-stage pipelines. 2006-10-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422006/380375null REMOTE http://pharmexec.findpharma.com/pharmexec/Articles/Born-Again/ArticleStandard/Article/detail/378064?contextCategoryId=39724&ref=25 Most people have never heard of psychotic depression, but they are familiar with the case of Andrea Yates, who tragically murdered her children during an episode of the disease. 2006-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412006/378064/TN_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412006/378064null XML http://pharmexec.findpharma.com/pharmexec/Global+Report/Global-Report-Please-Come-Back/ArticleStandard/Article/detail/378060?contextCategoryId=39724&ref=25 A new European collaboration of biotech, pharma, academia, and government takes up the challenge of boosting R&D. 2006-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412006/378060null XML http://pharmexec.findpharma.com/pharmexec/Thought+Leader/Smaller-is-Better/ArticleStandard/Article/detail/378065?contextCategoryId=39724&ref=25 New partnerships with nanobiotech firms are helping pharma companies overcome solubility problems and extend profitable product lifecycles. 2006-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412006/378065null XML http://pharmexec.findpharma.com/pharmexec/Articles/Learn-amp-Confirm/ArticleStandard/Article/detail/378070?contextCategoryId=39724&ref=25 In revamping its R&D department, Wyeth "really looked for people who were not going to give us the same old, 'This is how you do pharmaceutical development, dah-dah-dah,' but who could really think of different ways of doing things." 2006-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412006/378070null XML http://pharmexec.findpharma.com/pharmexec/Washington+Report/Washington-Report-New-Partnerships-Pursue-Old-Dise/ArticleStandard/Article/detail/369268?contextCategoryId=39724&ref=25 The PPP approach asks pharma to identify promising drugs and conduct pre-clinical tests, instead of paying for costly late-stage clinical trials. 2006-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362006/369268null XML http://pharmexec.findpharma.com/pharmexec/Articles/Benchmarking-AIDS/ArticleStandard/Article/detail/369277?contextCategoryId=39724&ref=25 Nothing reflects pharma's response to public-health crises in sharper detail than the industry's efforts to fight the AIDS epidemic. 2006-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362006/369277null XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/PharmExecs-2006-Forecast/ArticleStandard/Article/detail/256553?contextCategoryId=39724&ref=25 Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year—if you like roller coasters. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256553/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Thought-Leader-A-QampA-with-Graham-Allaway/ArticleStandard/Article/detail/256546?contextCategoryId=39724&ref=25 Some people are infected by HIV strains that are already resistant to FDA-approved drugs because they were transmitted by someone who developed resistance while receiving antiretroviral therapy. As a result, these patients often fail therapy. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256546/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/The-PharmExec-2005-Pipeline-Report/ArticleStandard/Article/detail/256552?contextCategoryId=39724&ref=25 Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256552/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/From-the-Editor-Double-Standard-Drugs/ArticleStandard/Article/detail/256545?contextCategoryId=39724&ref=25 The public is focused on drug safety, but the real issue isn't approval standards. It's the way drugs expand to unapproved new indications. Are you listening, Acomplia? 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256545/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/PE+Features/The-Avian-Few-Is-it-Too-Late-for-Pharma-to-Re-ente/ArticleStandard/Article/detail/256551?contextCategoryId=39724&ref=25 Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again—more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives—a figure the World Health Organization (WHO) quickly retracted. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256551/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Washington-Report-Big-Production/ArticleStandard/Article/detail/256547?contextCategoryId=39724&ref=25 FDA may be receiving fewer new drug applications for truly innovative products, but it has been overwhelmed this year with 800 abbreviated NDAs for generic drugs and thousands of supplements. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256547/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Global+Report/Global-Report-Wanted-Attention/ArticleStandard/Article/detail/256548?contextCategoryId=39724&ref=25 The biggest threat to the success of polio eradication is Nigeria, where the immunization program was suspended on religious grounds in some parts of the country in 2003 and 2004. 2005-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502005/256548/PE1205_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/From-the-Editor-Lost-World/ArticleStandard/Article/detail/197788?contextCategoryId=39724&ref=25 Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again. 2005-11-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472005/197788/110105_pe_cvr_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/PE+Features/Valeant-Pharmaceuticals-is-Soldiering-On/ArticleStandard/Article/detail/197794?contextCategoryId=39724&ref=25 Valeant is banking on Viramidine, a pro-drug of its longtime cash cow, ribavirin, to catapult the company to the next level. 2005-11-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472005/197794/110105_pe_cvr_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Changing-Diabetes/ArticleStandard/Article/detail/187083?contextCategoryId=39724&ref=25 Martin Soeters (pronounced soo't rs) has dedicated a quarter century—almost half his life—to the company at which he's now president of US operations. Novo Nordisk, where Soeters has worked since 1980—in various executive roles and locations, from The Netherlands (his homeland) to Belgium to France—is a leader in diabetes treatment, with the largest portfolio in the industry. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187083/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Washington-Report-Antivirals-Meeting-a-World-of-Ne/ArticleStandard/Article/detail/187077?contextCategoryId=39724&ref=25 Many still regard FDA's approach as costly and unnecessary. But the prospect of qualifying for purchase by PEPFAR is attracting applicants. The policy has helped bring news AIDS treatments to market. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187077/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Biopartnerships/Seven-Principles-for-Fostering-Partnerships/ArticleStandard/Article/detail/197776?contextCategoryId=39724&ref=25 The backbone of the business development process is a series of decision gates with agreed upon decision criteria, and clear expectations for the appropriate levels of research and analysis for each stage in the process. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472005/197776/PESupp_cv_tn_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Global+Report/Global-Report-Animal-Attacks/ArticleStandard/Article/detail/187078?contextCategoryId=39724&ref=25 UK courts are affirming the belief that medical research and drug development have made a huge contribution to people's quality of life, and that a small but vital part of that work involves the use of animals. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187078/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/DELETE/Backpage-Under-Surveillance/ArticleStandard/Article/detail/187091?contextCategoryId=39724&ref=25 You hear it often these days: Recent drug recalls have shaken the confidence people place in the pharmaceutical industry. While there's some truth to it, the reality is much more complex. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187091/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Biopartnerships/Successful-Alliances-Novartis-and-Idenix-Share-the/ArticleStandard/Article/detail/197775?contextCategoryId=39724&ref=25 When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472005/197775/PESupp_cv_tn_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Biopartnerships/Its-All-Academic-Biotechs-Looking-to-Universities/ArticleStandard/Article/detail/197778?contextCategoryId=39724&ref=25 Academic institutions look for a strong committment from the company's senior management, favorable deal terms, market depth in a specific therapeutic area, and alignment with the partner's core strategy. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472005/197778/PESupp_cv_tn_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Clear-Road-Ahead/ArticleStandard/Article/detail/187085?contextCategoryId=39724&ref=25 Increased availability of clinical-trials information allows patients to identify trials in which they may participate, assess safety issues, and easily register. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187085/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/From-the-Editor-No-Substitutes/ArticleStandard/Article/detail/187151?contextCategoryId=39724&ref=25 In an opinion piece in the September 8 New England Journal of Medicine, Harvard medical professor and long-time industry critic Jerry Avorn takes a whack at FDA, accusing the agency of practicing a level of science that wouldn’t pass muster anywhere else in research—science that’s only "good enough for government work."; 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187151/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Following-Science/ArticleStandard/Article/detail/187273?contextCategoryId=39724&ref=25 Growing by Indication, Genentech Has a New Type of Blockbuster 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187273/PE1005_CVR03_main.jpg HTML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Thought-Leader-Room-for-Improvement/ArticleStandard/Article/detail/187076?contextCategoryId=39724&ref=25 When you have a workable technology, the question becomes ‘To what do you apply this technology?’ and ‘Where do you spend your time?’ We really believed we would be most successful by spending a lot of time figuring out which drugs to work on and then working assiduously on those few products with huge potential. 2005-10-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422005/187076/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Global-Report-Kids-R-EU/ArticleStandard/Article/detail/177962?contextCategoryId=39724&ref=25 If the legislation passes, companies will be rewarded with a six-month extension of market exclusivity if they conduct pediatric trials. And under the proposal, companies that fail to comply can be penalized. 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177962/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/PE+Features/Building-Blockbusters/ArticleStandard/Article/detail/177965?contextCategoryId=39724&ref=25 Companies face a serious pipeline gap, partly because they focus too narrowly on scientific breakthroughs. Stakeholders also value convenient compounds with reduced side effects and fewer doses. 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177965/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/From-the-Editor-It-Never-Changes-Until-It-Does/ArticleStandard/Article/detail/177958?contextCategoryId=39724&ref=25 My doctor and I have two different visions of an avian influenza pandemic. She's picturing regular flu season, but worse. I'm imagining 1918. Does the conflict sound familiar? 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177958/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/Thought-Leader-Ecosystemic-Change/ArticleStandard/Article/detail/177959?contextCategoryId=39724&ref=25 Digital forms of image transmission, archiving, and education with the virtual microscope will revolutionize pathology. 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177959/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Current+Issue/2005-Industry-Audit/ArticleStandard/Article/detail/177964?contextCategoryId=39724&ref=25 Not surprisingly, the biotechs hold three of the top five rankings in percent of sales invested in R&D. Even more impressive, then, are the ratios for Big Pharmas like Schering-Plough and Eli Lilly, in third and fourth place, both at a bit more than 19 percent. 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177964/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Back+Page/Back-Page-Evolution-Its-Not-Right/ArticleStandard/Article/detail/178163?contextCategoryId=39724&ref=25 The pharmaceutical industry depends on good science. So what does it mean when a majority of the US population turns its back on one of the fundamental insights of modern biology? 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/178163/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/PE+Features/Biomarkers-Come-of-Age/ArticleStandard/Article/detail/177967?contextCategoryId=39724&ref=25 In a few years' time, or so the conventional wisdom goes, personalized medicine will become a reality, and many (or even most) new drugs will come to market supported by tests that will help physicians make the decision of who gets what drug, what's the appropriate dose, and who's in the greatest danger of serious side effects—all based on a better understanding of biological processes and newly available data from testing at the molecular level to characterize patients and disease. We're not there yet, of course. To date only a handful of drugs are accompanied by molecular-level diagnostic tests. At the 2005 Molecular Medicine Tri-Conference, Ian Massey, PhD, senior vice president and head of research and preclinical development at Roche, expressed the opinion that molecular diagnostics will only affect a few medicines in the near to mid-term. 2005-09-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362005/177967/PE_TN_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Thought+Leader/Making-Drugs-Smarter/ArticleStandard/Article/detail/175695?contextCategoryId=39724&ref=25 Imagine drugs that can detect one particular compound in a patient's body and respond to it by releasing a drug. They're not that far away. 2005-08-01T04:00:00Z XML